Approval of unaudited financial results for the quarter ended 30/06/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma's Board approved unaudited results for Q1 FY26. The company reported zero revenue from operations, with all earnings coming from 'Other Income' of Rs. 100.25 lakhs (vs Rs. 1.08 lakhs in Q1 FY25), which includes commission income. Total expenses were Rs. 10.89 lakhs, yielding a profit before tax of Rs. 89.36 lakhs and profit after tax of Rs. 66.87 lakhs (vs a loss of Rs. 3.40 lakhs in Q1 FY25). EPS stood at Rs. 0.48. The Board also accepted the resignation of the Manager, Mr. Ganpat Dhondu Salekar. Notably, paid-up equity capital rose from Rs. 589 lakhs to Rs. 1,397.03 lakhs, indicating a sizeable preferential allotment during the year.
While headline profit swung to positive, investors should note the company has no operating revenue and the entire profit comes from 'other income' (largely commissions), making earnings quality weak. The auditor flagged an Emphasis of Matter regarding inability to verify end-use of preferential allotment funds, possible undisclosed related-party transactions, and unclear recoverability of advances — all of which warrant close scrutiny by shareholders.